PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30594690-2 2019 The ameliorative potential of the AT1R blocker olmesartan (OLM) on oxidative stress and inflammatory cytokines has received considerable attention in recent years. olmesartan 47-57 angiotensin II receptor, type 1a Rattus norvegicus 34-38 32106816-7 2020 High-dose nitrate or olmesartan alone, and especially in combination, decreased the levels of PRA and angiotensin II and downregulated the CHF-induced expression of AT1R, alpha1A-, beta1-, and beta2-AR, and AT2R. olmesartan 21-31 angiotensin II receptor, type 1a Rattus norvegicus 165-169 26763849-4 2016 RGS2 mRNA expression significantly increased with Ang II stimulation, and this increase was almost completely abolished by olmesartan, a potent AT1R-specific blocker. olmesartan 123-133 angiotensin II receptor, type 1a Rattus norvegicus 144-148 24847907-6 2014 Increased ROS production induced by Ang II was inhibited by Ang II type 1 receptor (AT1) blockers (Olmesartan and Candesartan, ARB), a NADPH Oxidase inhibitor (apocynin), and mitochondrial KATP channels inhibitor (5-hydroxydecanoate, 5HD). olmesartan 99-109 angiotensin II receptor, type 1a Rattus norvegicus 60-82 24847907-6 2014 Increased ROS production induced by Ang II was inhibited by Ang II type 1 receptor (AT1) blockers (Olmesartan and Candesartan, ARB), a NADPH Oxidase inhibitor (apocynin), and mitochondrial KATP channels inhibitor (5-hydroxydecanoate, 5HD). olmesartan 99-109 angiotensin II receptor, type 1a Rattus norvegicus 84-87 23459599-1 2013 BACKGROUND: We investigated whether the antihypertensive actions of the angiotensin II (Ang II) receptor (AT(1)-R) blocker, olmesartan medoxomil, may in part be mediated by increased Ang-(1-7) in the absence of significant changes in plasma Ang II. olmesartan 124-134 angiotensin II receptor, type 1a Rattus norvegicus 72-113 24770651-5 2014 Administration of the AT1R antagonist olmesartan resulted in the restoration of the reduction of apelin and APJ expressions induced by AngII for 48 h in 3T3-L1 adipocytes. olmesartan 38-48 angiotensin II receptor, type 1a Rattus norvegicus 22-26 21602711-2 2011 The present study examines whether the AT1R blocker olmesartan improves peripheral nerve dysfunction in rats with type 2 diabetes. olmesartan 52-62 angiotensin II receptor, type 1a Rattus norvegicus 39-43 23389452-10 2013 In contrast, ANG II binding to OKP cells stably expressing rat AT(1A)Rs, which have a conserved AT(1)R-binding pocket with human AT(1)R, is efficiently inhibited by olmesartan. olmesartan 165-175 angiotensin II receptor, type 1a Rattus norvegicus 63-68 23389452-10 2013 In contrast, ANG II binding to OKP cells stably expressing rat AT(1A)Rs, which have a conserved AT(1)R-binding pocket with human AT(1)R, is efficiently inhibited by olmesartan. olmesartan 165-175 angiotensin II receptor, type 1a Rattus norvegicus 96-102 22160776-7 2012 Olmesartan medoxomil, an AT1R blocker, markedly reduced the proteinuria and infiltration of mononuclear cells, whereas spironolactone, a mineralocorticoid receptor blocker, did not. olmesartan 0-10 angiotensin II receptor, type 1a Rattus norvegicus 25-29 16331107-6 2006 In the AII-infused rats treated with olmesartan medoxomil, an AT1R blocker, we were interested to observe significant decreases in plasma TC and non-high-density lipoprotein (HDL)-cholesterol (C) (TC minus HDL-C), and liver cholesterol content were also decreased. olmesartan 37-47 angiotensin II receptor, type 1a Rattus norvegicus 62-66 19261744-4 2009 With olmesartan [Ang II type 1 receptor (AT1R) antagonist] pretreatment, p-ERK plateau levels decreased in a dose-dependent manner (EC(50) = 1.3 x 10(-8) M, maximal inhibition 50.6 +/- 11.0% at 10(-5) M); a similar effect was observed with RNA interference against Ang II type 1A receptor (AT(1A)R) and Tempol, a superoxide dismutase mimetic. olmesartan 5-15 angiotensin II receptor, type 1a Rattus norvegicus 17-39 19261744-4 2009 With olmesartan [Ang II type 1 receptor (AT1R) antagonist] pretreatment, p-ERK plateau levels decreased in a dose-dependent manner (EC(50) = 1.3 x 10(-8) M, maximal inhibition 50.6 +/- 11.0% at 10(-5) M); a similar effect was observed with RNA interference against Ang II type 1A receptor (AT(1A)R) and Tempol, a superoxide dismutase mimetic. olmesartan 5-15 angiotensin II receptor, type 1a Rattus norvegicus 41-45 19261744-4 2009 With olmesartan [Ang II type 1 receptor (AT1R) antagonist] pretreatment, p-ERK plateau levels decreased in a dose-dependent manner (EC(50) = 1.3 x 10(-8) M, maximal inhibition 50.6 +/- 11.0% at 10(-5) M); a similar effect was observed with RNA interference against Ang II type 1A receptor (AT(1A)R) and Tempol, a superoxide dismutase mimetic. olmesartan 5-15 angiotensin II receptor, type 1a Rattus norvegicus 290-295 21383952-0 2011 Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. olmesartan 0-10 angiotensin II receptor, type 1a Rattus norvegicus 15-18 21383952-3 2011 Here, we investigated whether olmesartan, an AT(1)R antagonist protects against experimental autoimmune myocarditis (EAM) by suppression of oxidative stress, endoplasmic reticulum (ER) stress and inflammatory cytokines. olmesartan 30-40 angiotensin II receptor, type 1a Rattus norvegicus 45-51 16380466-6 2006 Anti-megalin antisera and an AT(1)R blocker (olmesartan) were used to interfere with uptake via megalin and the AT(1)R, respectively. olmesartan 45-55 angiotensin II receptor, type 1a Rattus norvegicus 112-118 15291375-5 2004 RESULTS: Olmesartan, the active metabolite of olmesartan medoxomil, is a highly potent antagonist of the AT1 receptor. olmesartan 46-56 angiotensin II receptor, type 1a Rattus norvegicus 105-108 15879491-0 2005 Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. olmesartan 0-10 angiotensin II receptor, type 1a Rattus norvegicus 20-23 15291375-5 2004 RESULTS: Olmesartan, the active metabolite of olmesartan medoxomil, is a highly potent antagonist of the AT1 receptor. olmesartan 9-19 angiotensin II receptor, type 1a Rattus norvegicus 105-108 15291375-11 2004 CONCLUSIONS: AT1 receptor antagonists such as olmesartan represent a valid therapeutic option for the treatment of hypertension and other cardiovascular and renal diseases. olmesartan 46-56 angiotensin II receptor, type 1a Rattus norvegicus 13-16 12047043-10 2002 These results indicate that AT1 receptor blockade with olmesartan retards the progression of nephropathy associated with type 2 diabetes without affecting glucose metabolism, and that this renal protective effect is at least partly independent of the antihypertensive effect of the drug. olmesartan 55-65 angiotensin II receptor, type 1a Rattus norvegicus 28-31 12874087-0 2003 Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. olmesartan 31-41 angiotensin II receptor, type 1a Rattus norvegicus 16-19 12874087-11 2003 Moreover, the AT1 receptor antagonist olmesartan (CS866; week 12 to 16) essentially normalized blood pressure to 113+/-5.4 mm Hg (n=6, P<0.01 versus OVX and sham). olmesartan 38-48 angiotensin II receptor, type 1a Rattus norvegicus 14-17 12117316-0 2002 Trophic effect of olmesartan, a novel AT1R antagonist, on spinal motor neurons in vitro and in vivo. olmesartan 18-28 angiotensin II receptor, type 1a Rattus norvegicus 38-42 11791001-9 2002 These results suggest that RNH-6270 is a potent AT1 receptor antagonist and has anti-proliferative effects on VSMCs from SHR, which was not seen with an ACE inhibitor. olmesartan 27-35 angiotensin II receptor, type 1a Rattus norvegicus 48-51 11791001-10 2002 The growth inhibitory effect of RNH-6270 may be associated with the inhibition of growth factors via antagonism to AT1 receptors. olmesartan 32-40 angiotensin II receptor, type 1a Rattus norvegicus 115-118